Publication:
Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.

Simple item page
dc.contributor.authorsHussain, Maha; Tangen, Catherine M.; Higano, Celestia S.; Crawford, E. David; Liu, Glenn; Wilding, George; Prescott, Stephen; Akdas, Atif; Small, Eric Jay; Dawson, Nancy Ann; Donnelly, Bryan J.; Venner, Peter; Vaishampayan, Ulka N.; Schellhammer, Paul F.; Quinn, David I.; Raghavan, Derek; Vogelzang, Nicholas J.; Thompson, Ian Murchie
dc.date.accessioned2022-03-12T16:14:01Z
dc.date.accessioned2026-01-10T16:55:43Z
dc.date.available2022-03-12T16:14:01Z
dc.date.issued2012
dc.identifier.doi10.1200/jco.2012.30.18_suppl.4
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/225194
dc.identifier.wosWOS:000318009803701
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleIntermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.issue15
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume30

Files

Collections

Araştırma Çıktıları